Methodology for labeling proteins and peptides with lead-212 (212Pb).

[1]  M. Brechbiel,et al.  Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. , 2013, International journal of radiation oncology, biology, physics.

[2]  A. Feuchtinger,et al.  Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Brechbiel,et al.  212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease , 2012, Molecular Cancer Therapeutics.

[4]  Young-Seung Kim,et al.  An overview of targeted alpha therapy , 2012, Tumor Biology.

[5]  D. Neri,et al.  Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.

[6]  M. Brechbiel,et al.  Towards translation of 212Pb as a clinical therapeutic; getting the lead in! , 2011, Dalton transactions.

[7]  D. Goldenberg,et al.  New Antibody Conjugates in Cancer Therapy , 2010, TheScientificWorldJournal.

[8]  D. Milenic.  Antibody Engineering: Optimizing the Delivery Vehicle , 2010 .

[9]  M. Brechbiel,et al.  Improved efficacy of α‐particle–targeted radiation therapy , 2010 .

[10]  L. Jacobsson,et al.  Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.

[11]  M. Brechbiel,et al.  Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease , 2008, Clinical Cancer Research.

[12]  W. Oyen,et al.  Intracavitary radioimmunotherapy to treat solid tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.

[13]  R. Guilard,et al.  New Insights into the Complexation of Lead(II) by 1,4,7,10‐Tetrakis(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecane (DOTAM): Structural, Thermodynamic, and Kinetic Studies , 2008 .

[14]  A. Tolcher,et al.  Technology Insight: cytotoxic drug immunoconjugates for cancer therapy , 2007, Nature Clinical Practice Oncology.

[15]  M. Brechbiel,et al.  Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease , 2007, Clinical Cancer Research.

[16]  K. Schwarz,et al.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. , 2007, Cancer research.

[17]  M. Brechbiel,et al.  Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  A. Casadevall,et al.  Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases , 2005, Expert opinion on drug delivery.

[19]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[20]  P. Beaumier,et al.  Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. , 2005, Nuclear medicine and biology.

[21]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[22]  Hans-Jü Rgen Wester.  Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .

[23]  E. Kremmer,et al.  Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  M. Brechbiel,et al.  Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.

[25]  L. Chappell,et al.  Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. , 2004, Cancer biotherapy & radiopharmaceuticals.

[26]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[27]  J. Little,et al.  Stress signaling from irradiated to non-irradiated cells. , 2004, Current cancer drug targets.

[28]  K. Prise,et al.  Bystander responses induced by low LET radiation , 2003, Oncogene.

[29]  D. Milenic.  Monoclonal antibody-based therapy strategies: providing options for the cancer patient. , 2002, Current pharmaceutical design.

[30]  E. Kremmer,et al.  Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. , 2001, Cancer research.

[31]  L. Chappell,et al.  Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.

[32]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  L. Chappell,et al.  Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. , 1999, Nuclear medicine and biology.

[34]  T. Waldmann,et al.  Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  O. Gansow,et al.  The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. , 1996, International journal of radiation oncology, biology, physics.

[36]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  R. Howell,et al.  Relative biological effectiveness of alpha-particle emitters in vivo at low doses. , 1994, Radiation research.

[38]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[39]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[40]  A. Herbst,et al.  The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. , 1989, American journal of obstetrics and gynecology.